Especially, serum NfL levels were higher in RRMS patients than in age‐matched HCs, higher in active MS than in inactive MS, higher during relapses than in patients with a stable disease and higher in PMS than in RRMS patients with both platforms (Figure 2B). The gene discussed is NEFL; the disease is myeloid sarcoma.